GPC3 and neoplasm: To address one of the most important obstacles of solid tumor CAR-T therapy, which is poor CAR-T trafficking into the tumor sites, Pang and colleagues developed glypican 3- or mesothelin-redirected CAR-Ts engineered to express and secrete IL-7 and CCL19 and demonstrated that these CAR-Ts exhibited enhanced migration capacity and expansion rate in vitro (151).